多发性骨髓瘤的最新进展
Latest Development in Multiple Myeloma.
作者信息
Imai Yoichi
机构信息
Department of Hematology/Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 113-8654, Japan.
出版信息
Cancers (Basel). 2020 Sep 7;12(9):2544. doi: 10.3390/cancers12092544.
Abstract
Specialists in the field of multiple myeloma (MM) research have written a series of 12 articles (2 original articles, 10 reviews) in the Special Issue "Latest Development in Multiple Myeloma" [...].
摘要
多发性骨髓瘤（MM）研究领域的专家们在《多发性骨髓瘤的最新进展》特刊上撰写了一系列12篇文章（2篇原创文章，10篇综述）[...]。
相似文献
1
Latest Development in Multiple Myeloma.多发性骨髓瘤的最新进展
Cancers (Basel). 2020 Sep 7;12(9):2544. doi: 10.3390/cancers12092544.
2
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.抗 CD19 CAR T 细胞联合大剂量美法仑和自体干细胞移植治疗难治性多发性骨髓瘤。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.120505.
3
Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.微小残留病和浆细胞对数减少与年轻多发性骨髓瘤患者双自体干细胞移植后获得更好反应相关。
Cytometry B Clin Cytom. 2019 May;96(3):195-200. doi: 10.1002/cyto.b.21755. Epub 2018 Dec 13.
4
[Impact of minimal residual disease detection after treatment of multiple myeloma].[多发性骨髓瘤治疗后微小残留病检测的影响]
Orv Hetil. 2019 Mar;160(13):502-508. doi: 10.1556/650.2019.31353.
5
Current treatment options of T cell-associated immunotherapy in multiple myeloma.多发性骨髓瘤中 T 细胞相关免疫治疗的当前治疗选择。
Clin Exp Med. 2017 Nov;17(4):431-439. doi: 10.1007/s10238-017-0450-9. Epub 2017 Jan 24.
6
[CAR Technology and Its Application in Treatment of Multiple Myeloma--Review].[嵌合抗原受体技术及其在多发性骨髓瘤治疗中的应用——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):279-84. doi: 10.7534/j.issn.1009-2137.2016.01.054.
7
Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.靶向骨髓微环境中的免疫龛：多发性骨髓瘤免疫治疗的兴起。
Curr Cancer Drug Targets. 2017;17(9):782-805. doi: 10.2174/1568009617666170214103834.
8
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.靶向多发性骨髓瘤中的 B 细胞成熟抗原（BCMA）：基于 BCMA 的免疫疗法的潜在用途。
Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018.
9
Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.BCMA 靶向 CAR-T 免疫疗法治疗多发性骨髓瘤和复发性/难治性多发性骨髓瘤概述。
Scand J Immunol. 2020 Aug;92(2):e12910. doi: 10.1111/sji.12910. Epub 2020 Jun 17.
10
Chimeric antigen receptor T-cell therapy for multiple myeloma.嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤。
Int J Hematol. 2020 Apr;111(4):530-534. doi: 10.1007/s12185-020-02827-8. Epub 2020 Jan 25.
引用本文的文献
1
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.嵌合抗原受体T细胞（CAR-T）疗法在血液系统肿瘤和实体瘤治疗中的当前进展与挑战
Immunotargets Ther. 2025 Jun 27;14:655-680. doi: 10.2147/ITT.S519616. eCollection 2025.
2
Coexisting Thalassemia, Immune Thrombocytopenic Purpura, and Multiple Myeloma With Osteopenia: Complex Hematologic Case in an Adult Asian Male Patient.并存地中海贫血、免疫性血小板减少性紫癜和伴有骨质减少的多发性骨髓瘤：一名成年亚洲男性患者的复杂血液病例
Cureus. 2024 Dec 8;16(12):e75338. doi: 10.7759/cureus.75338. eCollection 2024 Dec.
3
Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations.循环微小RNA作为多发性骨髓瘤的辅助诊断生物标志物：系统评价、荟萃分析及建议
Front Oncol. 2021 Jul 8;11:698197. doi: 10.3389/fonc.2021.698197. eCollection 2021.
本文引用的文献
1
Targeting Multiple Myeloma through the Biology of Long-Lived Plasma Cells.通过长寿浆细胞生物学靶向多发性骨髓瘤
Cancers (Basel). 2020 Jul 30;12(8):2117. doi: 10.3390/cancers12082117.
2
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.KRAS基因外显子4突变影响人多发性骨髓瘤细胞系中的MEK/ERK和PI3K/AKT信号通路。
Cancers (Basel). 2020 Feb 16;12(2):455. doi: 10.3390/cancers12020455.
3
Multiple Myeloma: Available Therapies and Causes of Drug Resistance.多发性骨髓瘤：现有治疗方法及耐药原因
Cancers (Basel). 2020 Feb 10;12(2):407. doi: 10.3390/cancers12020407.
4
Proteasome Inhibitors for the Treatment of Multiple Myeloma.用于治疗多发性骨髓瘤的蛋白酶体抑制剂
Cancers (Basel). 2020 Jan 22;12(2):265. doi: 10.3390/cancers12020265.
5
Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma.自体干细胞移植后多克隆免疫球蛋白恢复是多发性骨髓瘤患者生存结局的独立预后因素。
Cancers (Basel). 2019 Dec 18;12(1):12. doi: 10.3390/cancers12010012.
6
Pain Management in Patients with Multiple Myeloma: An Update.多发性骨髓瘤患者的疼痛管理：最新进展
Cancers (Basel). 2019 Dec 17;11(12):2037. doi: 10.3390/cancers11122037.
7
Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma.嵌合抗原受体T细胞疗法治疗多发性骨髓瘤
Cancers (Basel). 2019 Dec 15;11(12):2024. doi: 10.3390/cancers11122024.
8
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies.探索多发性骨髓瘤的治愈方法：新治疗策略综述
Cancers (Basel). 2019 Dec 13;11(12):2015. doi: 10.3390/cancers11122015.
9
Immunotherapy for Multiple Myeloma.多发性骨髓瘤的免疫疗法
Cancers (Basel). 2019 Dec 12;11(12):2009. doi: 10.3390/cancers11122009.
10
Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma.多发性骨髓瘤患者中乙型肝炎病毒的再激活
Cancers (Basel). 2019 Nov 19;11(11):1819. doi: 10.3390/cancers11111819.
Zotero 插件